Document is current
Any future updates will be listed below
-
Authors
Ferrera, Loretta
Cappiello, Floriana
Venturini, Arianna
Lu, Hexin
Casciaro, Bruno
Cappella, Giacomo
Bontempi, Giulio
Corrente, Alessandra
Strippoli, Raffaele
Zara, Federico
Di, Y. Peter
Galietta, Luis J. V.
Mori, Mattia
Mangoni, Maria Luisa https://orcid.org/0000-0002-5991-5868
-
Funding
Funding for this research was provided by:
Fondazione per la Ricerca sulla Fibrosi Cistica (FFC#4/2022 Delegazione FFC Ricerca di Roma e della Franciacorta e Val Camonica)
EU’s NextGeneration EU-MUR PNRR Extended Partnership initiative on Emerging Infectious Diseases (PE00000007)
EU’s NextGeneration EU-MUR PNRR Extended Partnership initiative on Emerging Infectious Diseases (INF-ACT)
EU’s NextGeneration EU-MUR PNRR Extended Partnership initiative on Emerging Infectious Diseases (PE00000007)
EU’s NextGeneration EU-MUR PNRR Extended Partnership initiative on Emerging Infectious Diseases (INF-ACT)
National Institutes of Health (R01 AI176537)
Sapienza Università di Roma (RM12117A5D5A92A4)
Università degli Studi di Roma La Sapienza
- License Information
-
More Information
Article History
Received: 8 November 2024
Revised: 25 January 2025
Accepted: 19 February 2025
First Online: 18 March 2025
Declarations
:
: The authors declare no conflict of interest.
: The study on bronchial cells to investigate the effect of the peptides on CFTR was conducted according to the guidelines of the Declaration of Helsinki and approved by the Ethics Committee of the IRCCS Istituto Giannina Gaslini, Genova (24 September 2010; Number: 182). Informed consent was obtained from all subjects involved in the study.
: The study on animals was conducted according to a protocol (protocol 23083347) approved by the Institutional Animal Care and Use Committee (IACUC) of the University of Pittsburgh based on the NIH guide for the care and use of laboratory animals.
